However, surprisingly, the concurrent findings of a JAK2 V617F mutation raised more challenging questions and included in the differential diagnosis PMF or a hybrid MDS/MPN neoplasm that was unclassifiable. This evidence concerns the gene JAK2 and myeloproliferative disorder.